These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26655300)

  • 1. Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis.
    Yamada K; Noguchi K; Komeno T; Furuta Y; Nishizono A
    J Infect Dis; 2016 Apr; 213(8):1253-61. PubMed ID: 26655300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reevaluation of the efficacy of favipiravir against rabies virus using in vivo imaging analysis.
    Yamada K; Noguchi K; Kimitsuki K; Kaimori R; Saito N; Komeno T; Nakajima N; Furuta Y; Nishizono A
    Antiviral Res; 2019 Dec; 172():104641. PubMed ID: 31672666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re-evaluating the effect of Favipiravir treatment on rabies virus infection.
    Banyard AC; Mansfield KL; Wu G; Selden D; Thorne L; Birch C; Koraka P; Osterhaus ADME; Fooks AR
    Vaccine; 2019 Aug; 37(33):4686-4693. PubMed ID: 29132993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-d-N
    Konishi K; Kusakabe S; Kawaguchi N; Shishido T; Ito N; Harada M; Inoue S; Maeda K; Hall WW; Orba Y; Sawa H; Sasaki M; Sato A
    Antiviral Res; 2024 Sep; 229():105977. PubMed ID: 39089332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of the antiviral drug favipiravir on rabies immunoglobulin for post-exposure prophylaxis of rabies in mice model with category III-like exposures.
    Kimitsuki K; Khan S; Kaimori R; Yahiro T; Saito N; Yamada K; Nakajima N; Komeno T; Furuta Y; Quiambao BP; Virojanapirom P; Hemachudha T; Nishizono A
    Antiviral Res; 2023 Jan; 209():105489. PubMed ID: 36513207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Vaccine-Induced Extrafollicular Pathway of B Cell Differentiation Improves Rabies Postexposure Prophylaxis.
    Haley SL; Tzvetkov EP; Meuwissen S; Plummer JR; McGettigan JP
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28148792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of Marburg virus with orally administrated T-705 (Favipiravir) in a mouse model.
    Zhu W; Zhang Z; He S; Wong G; Banadyga L; Qiu X
    Antiviral Res; 2018 Mar; 151():39-49. PubMed ID: 29369776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of in vitro inhibitory potential of type-I interferons and different antiviral compounds on rabies virus replication.
    Marosi A; Forgách P; Gyuranecz M; Sulyok KM; Bakonyi T
    Vaccine; 2019 Aug; 37(33):4663-4672. PubMed ID: 29459063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever.
    Oestereich L; Rieger T; Lüdtke A; Ruibal P; Wurr S; Pallasch E; Bockholt S; Krasemann S; Muñoz-Fontela C; Günther S
    J Infect Dis; 2016 Mar; 213(6):934-8. PubMed ID: 26531247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of future rabies biologics and antiviral drugs.
    Smith TG; Wu X; Franka R; Rupprecht CE
    Adv Virus Res; 2011; 79():345-63. PubMed ID: 21601054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aptamers targeting rabies virus-infected cells inhibit street rabies virus in vivo.
    Liang HR; Hu GQ; Li L; Gao YW; Yang ST; Xia XZ
    Int Immunopharmacol; 2014 Aug; 21(2):432-8. PubMed ID: 24735817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing T-705 (favipiravir) treatment of severe influenza B virus infection in the immunocompromised mouse model.
    Pascua PNQ; Marathe BM; Vogel P; Webby RJ; Govorkova EA
    J Antimicrob Chemother; 2019 May; 74(5):1333-1341. PubMed ID: 30715325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. λ-Carrageenan P32 Is a Potent Inhibitor of Rabies Virus Infection.
    Luo Z; Tian D; Zhou M; Xiao W; Zhang Y; Li M; Sui B; Wang W; Guan H; Chen H; Fu ZF; Zhao L
    PLoS One; 2015; 10(10):e0140586. PubMed ID: 26465753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribavirin-related compounds exert in vitro inhibitory effects toward rabies virus.
    Anindita PD; Sasaki M; Okada K; Ito N; Sugiyama M; Saito-Tarashima N; Minakawa N; Shuto S; Otsuguro S; Ichikawa S; Matsuda A; Maenaka K; Orba Y; Sawa H
    Antiviral Res; 2018 Jun; 154():1-9. PubMed ID: 29601893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus.
    Bixler SL; Bocan TM; Wells J; Wetzel KS; Van Tongeren SA; Garza NL; Donnelly G; Cazares LH; Soloveva V; Welch L; Epstein C; Liang LF; Giesing D; Lenk R; Bavari S; Warren TK
    Antiviral Res; 2018 Mar; 151():50-54. PubMed ID: 29289664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rabies encephalitis in a child: a failure of rabies post exposure prophylaxis?
    Tinsa F; Borgi A; Jahouat I; Boussetta K
    BMJ Case Rep; 2015 Jan; 2015():. PubMed ID: 25589528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
    Julander JG; Shafer K; Smee DF; Morrey JD; Furuta Y
    Antimicrob Agents Chemother; 2009 Jan; 53(1):202-9. PubMed ID: 18955536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ifit2 Is a Restriction Factor in Rabies Virus Pathogenicity.
    Davis BM; Fensterl V; Lawrence TM; Hudacek AW; Sen GC; Schnell MJ
    J Virol; 2017 Sep; 91(17):. PubMed ID: 28637751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced protection against experimental Junin virus infection through the use of a modified favipiravir loading dose strategy.
    Gowen BB; Westover JB; Sefing EJ; Van Wettere AJ; Bailey KW; Wandersee L; Komeno T; Furuta Y
    Antiviral Res; 2017 Sep; 145():131-135. PubMed ID: 28780425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.
    Sissoko D; Laouenan C; Folkesson E; M'Lebing AB; Beavogui AH; Baize S; Camara AM; Maes P; Shepherd S; Danel C; Carazo S; Conde MN; Gala JL; Colin G; Savini H; Bore JA; Le Marcis F; Koundouno FR; Petitjean F; Lamah MC; Diederich S; Tounkara A; Poelart G; Berbain E; Dindart JM; Duraffour S; Lefevre A; Leno T; Peyrouset O; Irenge L; Bangoura N; Palich R; Hinzmann J; Kraus A; Barry TS; Berette S; Bongono A; Camara MS; Chanfreau Munoz V; Doumbouya L; Souley Harouna ; Kighoma PM; Koundouno FR; Réné Lolamou ; Loua CM; Massala V; Moumouni K; Provost C; Samake N; Sekou C; Soumah A; Arnould I; Komano MS; Gustin L; Berutto C; Camara D; Camara FS; Colpaert J; Delamou L; Jansson L; Kourouma E; Loua M; Malme K; Manfrin E; Maomou A; Milinouno A; Ombelet S; Sidiboun AY; Verreckt I; Yombouno P; Bocquin A; Carbonnelle C; Carmoi T; Frange P; Mely S; Nguyen VK; Pannetier D; Taburet AM; Treluyer JM; Kolie J; Moh R; Gonzalez MC; Kuisma E; Liedigk B; Ngabo D; Rudolf M; Thom R; Kerber R; Gabriel M; Di Caro A; Wölfel R; Badir J; Bentahir M; Deccache Y; Dumont C; Durant JF; El Bakkouri K; Gasasira Uwamahoro M; Smits B; Toufik N; Van Cauwenberghe S; Ezzedine K; D'Ortenzio E; Pizarro L; Etienne A; Guedj J; Fizet A; Barte de Sainte Fare E; Murgue B; Tran-Minh T; Rapp C; Piguet P; Poncin M; Draguez B; Allaford Duverger T; Barbe S; Baret G; Defourny I; Carroll M; Raoul H; Augier A; Eholie SP; Yazdanpanah Y; Levy-Marchal C; Antierrens A; Van Herp M; Günther S; de Lamballerie X; Keïta S; Mentre F; Anglaret X; Malvy D;
    PLoS Med; 2016 Mar; 13(3):e1001967. PubMed ID: 26930627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.